Inflammatory breast cancer
Breast Cancer Essentials: Perspectives for Surgeons, Page: 623-634
2021
- 10Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Captures10
- Readers10
- 10
Book Chapter Description
Inflammatory breast cancer is an aggressive, poor prognosis breast cancer subtype, comprising less than 5% of all mammary malignancies. Due to the radical involvement of skin, it is generally included in the "chest wall disease" spectrum of breast tumors. IBC represents a peculiar clinical entity of breast cancer, characterized by inflammatory signs and symptoms, edema of the breast, and a dire prognosis. No pathognomonic pathology finding is required to confirm the diagnosis, though suggestive ones can be described. The management of IBC is always multidisciplinary, addressing the appropriate sequence of integrated and multimodal treatments to increase the locoregional control and reduce the risk of metastatic spread and recurrence, preserving the quality of life and preventing the chest wall dissemination. Systemic staging is always recommended, to rule out the presence of distant metastases. No role for conservative surgery is currently endorsed; intensity and selection of both radiation therapy and chemotherapy must be personalized, according to the clinical response to primary systemic chemotherapy, the clinicopathological features of the disease, occurrence of pathological complete response, and tolerance of therapy. For the poor prognosis of nonresponders and recurrent patients, research development is implementing strategies to increase the rates of curable resections, adding on immunotherapy and targeted and biologic agents, and prolong the control of advanced disease, maximizing the quality of life.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85159818637&origin=inward; http://dx.doi.org/10.1007/978-3-030-73147-2_55; https://link.springer.com/10.1007/978-3-030-73147-2_55; https://link.springer.com/content/pdf/10.1007/978-3-030-73147-2_55; https://dx.doi.org/10.1007/978-3-030-73147-2_55; https://link.springer.com/chapter/10.1007/978-3-030-73147-2_55
Springer Science and Business Media LLC
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know